Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

TikTok creator Sydney Towle has died at the age of 26 after a three-year battle with cholangiocarcinoma, a rare and aggressive bile duct cancer.

Her family announced her death on social media on Wednesday (Aug. 5), sharing a photo of Towle standing on a mountain peak alongside the message: "Rest in Peace Sydney Elizabeth Towle. An endless ray of sunshine. A daughter, a sister and friend to so many."

"We will always love you so much, Sydney. I am so proud of how hard you fought. I love you," read the caption.

Her older brother, Austin Towle, also shared the tribute on his TikTok account, calling her the "best sister ever."

Sydney Towle: Entered Hospice Days Before Her Death

A day before announcing her death, Austin revealed that Sydney had entered hospice care. The post showed family and friends gathered around her hospital bed.

"Sydney has been moved to hospice and is surrounded by her friends and family. Thank you all for your love and support❤️," he wrote.

Sydney Towle: Rare Bile Duct Cancer at 23

Also read: Candida auris: US CDC Reports 3,437 Cases of Deadly Superbug In 27 States

Towle was diagnosed with cholangiocarcinoma at the age of 23, a rare cancer that develops in the bile ducts and is most commonly diagnosed in people over 50.

Her diagnosis followed a lump and a burning sensation in her abdomen in 2023. Initially believed to be a hernia, it was later confirmed to be bile duct cancer.

Sydney Towle Documented Cancer Journey Online

Following her diagnosis, Towle documented her cancer journey on social media, saying that sharing her experience gave her a "purpose." She built a community of more than one million followers across TikTok and Instagram. Over the course of her illness, she underwent several surgeries, multiple rounds of chemotherapy and immunotherapy, and participated in clinical trials.

In an interview with TODAY.com in November 2024, Towle said five months of chemotherapy and immunotherapy had reduced the size of her tumor, allowing surgeons to remove most of it. However, some cancer remained lining her liver, and doctors planned regular scans to monitor it.

A later MRI revealed a lesion that doubled in size within a month.

She later moved to New York City, where she began working with a new medical team to develop another treatment plan.

Cancer Continued to Progress

Read More: Severe COVID-19 Can Reactivate Dormant Viruses, May Fuel Long COVID Symptoms: Study

In a TikTok video posted on May 17, 2026, Towle revealed that the cancer had spread to her peritoneum, the membrane lining the abdomen and pelvis.

Two days later, she said her oncologist recommended stopping active treatment and transitioning to end-of-life care.

"I said, 'No.' So, we are switching hospitals," Towle said. "We're not at the point where we're giving up."

On June 8, she shared that doctors had found tumors in her lungs. Despite undergoing further surgery, chemotherapy and immunotherapy over the following weeks, her health continued to decline. On July 21, she revealed she had been hospitalized for about a month while waiting to learn whether her treatments were working.

Her social media accounts fell silent soon after. On Aug. 4, her brother announced she had been moved to hospice care. A day later, her family confirmed that she had died, surrounded by loved ones.

What Is Cholangiocarcinoma?

Cholangiocarcinoma is a rare cancer that develops in the bile ducts—the slender tubes that carry bile, a digestive fluid, from the liver to the gallbladder and small intestine.

According to the Mayo Clinic, the disease occurs most often in people over the age of 50, although it can develop at any age. It is frequently diagnosed at an advanced stage, making treatment more challenging.

Signs and Symptoms include

• Yellowing of the skin and the whites of the eyes (jaundice)
• Intense itching
• White- or clay-colored stools
• Dark urine
• Fatigue
• Pain in the upper right side of the abdomen
• Unexplained weight loss
• Fever
• Night sweats

The US has reported 3,437 cases of the drug-resistant fungus Candida auris across 27 states so far this year, according to the latest data from the US Centers for Disease Control and Prevention (CDC).

The figure is about 1,000 fewer than the 4,290 cases reported during the same period last year.

The states reporting the highest number of cases this year are:

• California: 873
• Texas: 433
• Tennessee: 283

The CDC clarified that an increase in reported cases does not necessarily mean the fungus is spreading more rapidly than usual.

"An increasing number of cases does not mean the fungus is transmitting at a more rapid pace than usual," the CDC said.

The agency added that while C. auris cases continue to rise every year, the rate of increase has slowed since 2022.

Most Strains Resistant to Common Antifungal Drugs

A CDC analysis published earlier this year, based on 8,033 C. auris samples collected in 2022 and 2023, found:

• More than 95% were resistant to fluconazole, a first-line antifungal drug.
• 15% were resistant to amphotericin B.
• 1% were resistant to echinocandins.
• Fewer than 1% were resistant to all three major antifungal drug classes.

Why Is Candida auris a Concern?

Candida auris is a type of fungus that can cause serious infections in the human body. It was first identified in 2009.

The CDC said that the drug-resistant fungus continues to pose a major challenge for hospitals, nursing homes, and other healthcare facilities because it is difficult to treat and control.

"Candida auris is an emerging yeast that is frequently resistant to antifungal drugs. C. auris can cause invasive infections associated with high mortality and can colonize patients asymptomatically, which facilitates transmission in health care settings," the CDC said.

"Since it was first reported in the United States in 2016, C. auris has been identified in multiple states, with increasing numbers of cases reported annually. Monitoring national trends in cases identified through clinical testing and screening for colonization is critical to guide infection prevention and control efforts," it added.

Why Is Candida auris So Difficult to Control?

Unlike many other infections, Candida auris spreads easily through contaminated medical equipment and direct person-to-person contact. It can also survive for long periods on surfaces and is resistant to many commonly used disinfectants, making outbreaks difficult to contain once the fungus enters a healthcare facility.

Health officials say the steady rise in cases each year points to ongoing transmission in healthcare settings.

Symptoms and Health Risks

Candida auris can infect:

• The bloodstream
• Wounds
• Ears
• Other parts of the body

Symptoms vary depending on the site and severity of the infection. Some people may carry the fungus without showing any symptoms.

The CDC noted that most people who develop Candida auris infections are already seriously ill, making it difficult to determine how much the fungus contributes to death compared with their underlying medical conditions.

The fungus is particularly concerning in hospitals and nursing homes because it can survive on surfaces such as doorknobs, counters, and bed rails. Its resistance to multiple antifungal drugs makes infections difficult to treat and eliminate.

English actor and former Blue Peter presenter Peter Duncan recently urged health authorities to make focal therapy more available for prostate cancer patients. He said after describing the treatment as "life-changing" following his own diagnosis in 2019.

This comes as new evidence has been emerging that the minimally invasive approach can offer satisfactory cancer control compared to traditional treatments, while also significantly reducing long-term side effects.

The 72-year-old broadcaster revealed that he was initially offered a prostatectomy, a surgery that removes the entire prostate gland. Instead, he opted for focal therapy, a targeted treatment that destroys only the cancerous portion of the prostate while preserving healthy tissue.

"It was a complete success, and I've only experienced very minor after-effects, allowing me to continue with my life as before," Duncan said, while backing Prostate Cancer UK's campaign for wider NHS access to the treatment. "Many men aren't given the same chance I was, and that needs to change."

Importance Of Focal Therapy In Prostate Cancer Treatment

Also read: Tadalafil: Common Male-Potency Drug May Raise Glaucoma Risk In Men, Finds Study

Duncan's campaign comes amid growing clinical evidence supporting focal therapy for selected patients with localised prostate cancer.

A recent report from researchers at Imperial College London and Imperial College Healthcare NHS Trust found that focal therapy shows promise in cancer treatment compared to surgery and radiotherapy while causing far fewer complications in some patients.

Amy Rylance, Director of Health Services, Equity and Improvement at Prostate Cancer UK, said the delay in wider approval is leaving thousands of men with no access to treatments that could preserve their quality of life.

"Without a timeline from NICE, we simply don't know how long men will have to wait for approval on the NHS," she said. "Thousands of men will have to deal with life-changing side effects simply because of their postcode."

More About Focal Therapy

Also read: WHO Cancer Agency Flags 3 Common Medicines As Carcinogenic: What It Means For Millions Of Patients

Unlike prostatectomy or radiotherapy, focal therapy targets only the tumour inside the prostate. The treatment may use high-intensity focused ultrasound (HIFU) or cryotherapy to destroy cancer cells while preserving the surrounding healthy tissue.

Because the rest of the prostate and surrounding nerves are preserved, patients may generally face a much lower risk of urinary incontinence, erectile dysfunction and bowel problems.

Focal therapy is not suitable for everyone. Specialists say it is generally considered for men with localised, clinically significant prostate cancer where imaging and biopsy show that the tumour can be accurately targeted.

Patients still require long-term monitoring after treatment to ensure the cancer has not returned or progressed.

Can Focal Therapy Help?

Prostate cancer is the most commonly diagnosed cancer in men in the UK. According to Prostate Cancer UK, around one in eight men will be diagnosed during their lifetime, with the risk increasing with age, family history and Black ethnicity.

While surgery and radiotherapy remain the standard treatment options to treat prostate cancer, advocates argue that expanding access to focal therapy could help thousands of eligible men receive effective treatment with fewer long-term side effects.

Duncan hopes sharing his own experience will encourage both policymakers and patients to consider the option where appropriate.